G Saglio

Summary

Affiliation: University of Turin
Country: Italy

Publications

  1. pmc Iron chelation therapy in myelodysplastic syndromes
    Emanuela Messa
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Regione Gonzole 10, 10043 Orbassano TO, Italy
    Adv Hematol 2010:756289. 2010
  2. doi request reprint Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia
    Alessandro Morotti
    University Turin, San Luigi Hospital, Division of Hematology and Internal Medicine, Department of Oncology, Orbassano Turin, Italy
    Expert Opin Biol Ther 14:287-99. 2014
  3. pmc Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms
    Enrico Bracco
    Division of Hematology and Internal Medicine, Department of Oncology, University of Turin, Turin, Italy
    BMC Cancer 13:348. 2013
  4. ncbi request reprint Practical monitoring of chronic myelogenous leukemia: when to change treatment
    Giuseppe Saglio
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, San Luigi Gonzaga University Hospital, Turin, Italy
    J Natl Compr Canc Netw 10:121-9. 2012
  5. ncbi request reprint First-line therapy for chronic myeloid leukemia: new horizons and an update
    Giuseppe Saglio
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Clin Lymphoma Myeloma Leuk 10:169-76. 2010
  6. ncbi request reprint Abl: the prototype of oncogenic fusion proteins
    G Saglio
    Dept of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano Torino, Italy
    Cell Mol Life Sci 61:2897-911. 2004
  7. doi request reprint New therapeutic approaches and prognostic factors in chronic myeloid leukemia
    Giuseppe Saglio
    Division of Haematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy
    Leuk Lymphoma 49:625-8. 2008
  8. ncbi request reprint Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily
    Giuseppe Saglio
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Cancer 116:3852-61. 2010
  9. ncbi request reprint Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    Giuseppe Saglio
    University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
    N Engl J Med 362:2251-9. 2010
  10. ncbi request reprint Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia
    Giuseppe Saglio
    Dept of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043, Orbassano Torino, Italy
    Ann N Y Acad Sci 1028:423-31. 2004

Detail Information

Publications94

  1. pmc Iron chelation therapy in myelodysplastic syndromes
    Emanuela Messa
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Regione Gonzole 10, 10043 Orbassano TO, Italy
    Adv Hematol 2010:756289. 2010
    ..We also give an overview of clinical guidelines for chelation in MDS published to date and some perspectives for the future...
  2. doi request reprint Kinase-inhibitor-insensitive cancer stem cells in chronic myeloid leukemia
    Alessandro Morotti
    University Turin, San Luigi Hospital, Division of Hematology and Internal Medicine, Department of Oncology, Orbassano Turin, Italy
    Expert Opin Biol Ther 14:287-99. 2014
    ..Notably, in CML, additional cellular mechanisms promote LSC survival and maintenance, rendering these cells able to survive even in the presence of TKI and to eventually promote relapse...
  3. pmc Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms
    Enrico Bracco
    Division of Hematology and Internal Medicine, Department of Oncology, University of Turin, Turin, Italy
    BMC Cancer 13:348. 2013
    ..Mutation(s) of the JAK2 gene (V617F) has been described in a significant proportion of Philadelphia negative Myeloproliferative Neoplasms (MPN) patients and its detection is now a cornerstone in the diagnostic algorithm...
  4. ncbi request reprint Practical monitoring of chronic myelogenous leukemia: when to change treatment
    Giuseppe Saglio
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, San Luigi Gonzaga University Hospital, Turin, Italy
    J Natl Compr Canc Netw 10:121-9. 2012
    ....
  5. ncbi request reprint First-line therapy for chronic myeloid leukemia: new horizons and an update
    Giuseppe Saglio
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Clin Lymphoma Myeloma Leuk 10:169-76. 2010
    ..In the absence of trials comparing novel strategies, the synthesis of emerging data from next-generation agents and modified imatinib-based strategies is likely to be a key area of debate during the next few years...
  6. ncbi request reprint Abl: the prototype of oncogenic fusion proteins
    G Saglio
    Dept of Clinical and Biological Sciences, University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano Torino, Italy
    Cell Mol Life Sci 61:2897-911. 2004
    ....
  7. doi request reprint New therapeutic approaches and prognostic factors in chronic myeloid leukemia
    Giuseppe Saglio
    Division of Haematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy
    Leuk Lymphoma 49:625-8. 2008
    ..Understanding exactly the mechanisms leading to genomic instability of the Ph-positive cells represents therefore the real challenge for the near future...
  8. ncbi request reprint Dasatinib in imatinib-resistant or imatinib-intolerant chronic myeloid leukemia in blast phase after 2 years of follow-up in a phase 3 study: efficacy and tolerability of 140 milligrams once daily and 70 milligrams twice daily
    Giuseppe Saglio
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Cancer 116:3852-61. 2010
    ..In the current report, the results for patients with CML in blast phase after 2 years of follow-up are reported...
  9. ncbi request reprint Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia
    Giuseppe Saglio
    University of Turin, San Luigi Gonzaga Hospital, Orbassano, Turin, Italy
    N Engl J Med 362:2251-9. 2010
    ..We evaluated the efficacy and safety of nilotinib, as compared with imatinib, in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia (CML) in the chronic phase...
  10. ncbi request reprint Rational approaches to the design of therapeutics targeting molecular markers: the case of chronic myelogenous leukemia
    Giuseppe Saglio
    Dept of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043, Orbassano Torino, Italy
    Ann N Y Acad Sci 1028:423-31. 2004
    ..In spite of its low incidence, CML remains a paradigmatic model for understanding the pathogenesis and therapeutic options of human leukemias...
  11. ncbi request reprint Glivec and CML: a lucky date
    G Saglio
    Department of Clinical and Biological Sciences, University of Turin, Hospital S Luigi Gonzaga, Obassano, Torino, Italy
    J Biol Regul Homeost Agents 18:246-51. 2004
    ....
  12. doi request reprint Molecular monitoring in patients with chronic myelogenous leukemia
    Giuseppe Saglio
    Department of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Orbassano Torino, Italy
    Curr Hematol Malig Rep 3:65-71. 2008
    ..The early detection and the characterization of these mutations may allow timely and appropriate treatment to overcome resistance...
  13. ncbi request reprint Increase sensitivity to chemotherapeutical agents and cytoplasmatic interaction between NPM leukemic mutant and NF-kappaB in AML carrying NPM1 mutations
    D Cilloni
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy
    Leukemia 22:1234-40. 2008
    ..These data, taken together, may provide a possible explanation for the increased rate of chemosensitivity observed among the NPMc+ patients...
  14. ncbi request reprint NF-kB inhibition as a strategy to enhance etoposide-induced apoptosis in K562 cell line
    A Morotti
    Division of Haematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy
    Am J Hematol 81:938-45. 2006
    ..Both inhibitors and stable expression of SR-IkB are associated with down-modulation of the antiapoptotic protein Bcl-xL, suggesting that the survival pathway activated by Etoposide involves NF-kB-mediated Bcl-xL expression...
  15. ncbi request reprint BCR-ABL disrupts PTEN nuclear-cytoplasmic shuttling through phosphorylation-dependent activation of HAUSP
    A Morotti
    1 Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA 2 Division of Hematology and Internal Medicine, Department of Oncology, San Luigi Hospital, University of Turin, Turin, Italy
    Leukemia 28:1326-33. 2014
    ..We therefore identify a new proto-oncogenic mechanism whereby BCR-ABL antagonizes the nuclear function of the PTEN tumor suppressor, with important therapeutic implications for the eradication of CML minimal residual disease. ..
  16. ncbi request reprint The NF-kappaB pathway blockade by the IKK inhibitor PS1145 can overcome imatinib resistance
    D Cilloni
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy
    Leukemia 20:61-7. 2006
    ..Our data provide the rational for a new therapeutic approach, which combines Imatinib and the IKK inhibitor PS1145 in CML resistant patients...
  17. ncbi request reprint WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia
    D Cilloni
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Leukemia 21:1442-50. 2007
    ....
  18. ncbi request reprint Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes
    Daniela Cilloni
    Division of Hematology and Internal Medicne, Department of Clinical and Biological Sciences, University of Turin, Italy
    J Clin Oncol 21:1988-95. 2003
    ..To determine whether pattern of WT1 gene expression is a useful marker for establishing prognosis and tracking disease progression in patients with myelodysplastic syndromes (MDS)...
  19. ncbi request reprint A young man with persistent eosinophilia
    E Messa
    Department of Clinical and Biological Sciences, University of Turin, Regione Gonzole 10, S Luigi Hospital, Orbassano, Turin, Italy
    Intern Emerg Med 2:107-12. 2007
  20. ncbi request reprint Two new translocations involving the 11q23 region map outside the MLL locus in myeloid leukemias
    Emilia Giugliano
    Medicina Interna II, Dipartimento di Scienze Cliniche e Biologiche, Osp S Luigi Gonzaga, Orbassano, Italy
    Haematologica 87:1014-20. 2002
    ..In these two patients, involvement of the MLL gene was analyzed by molecular cytogenetic techniques which also allowed a more precise mapping of the breakpoints...
  21. ncbi request reprint Valproate enhances imatinib-induced growth arrest and apoptosis in chronic myeloid leukemia cells
    Alessandro Morotti
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Cancer 106:1188-96. 2006
    ..The objective of this study was to evaluate the ability of the clinically available histone deacetylase (HDAC) inhibitor valproate to enhance the cytotoxicity of the Bcr-Abl inhibitor imatinib in imatinib-resistant cell lines...
  22. ncbi request reprint WT1 overexpression in acute myeloid leukemia and myelodysplastic syndromes
    Daniela Cilloni
    Department of Clinical and Biological Sciences, University of Turin, Italy
    Methods Mol Med 125:199-211. 2006
    ..In this chapter, we describe the method for the quantification of WT1 transcript by real-time polymerase chain reaction...
  23. ncbi request reprint CML: a model for targeted therapy
    Daniela Cilloni
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Best Pract Res Clin Haematol 22:285-94. 2009
    ..There is an incomplete understanding of the so-called genomic instability that underlies the production of the fusion gene and predisposes the Ph-positive clone to acquire further genetic events leading to advanced-phase disease...
  24. ncbi request reprint Deferasirox treatment improved the hemoglobin level and decreased transfusion requirements in four patients with the myelodysplastic syndrome and primary myelofibrosis
    E Messa
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
    Acta Haematol 120:70-4. 2008
    ..The biological mechanism of action of deferasirox, an effect which is not shared by other iron chelators, is still obscure and requires further investigations...
  25. doi request reprint Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall surviva
    Marco Ladetto
    Divisione Universitaria di Ematologia, Cattedra di Ematologia, Torino, Italy
    Blood 111:4004-13. 2008
    ..This trial was registered at www.clinicaltrials.gov as no. NCT00435955...
  26. ncbi request reprint Nuclear factor kB as a target for new drug development in myeloid malignancies
    Daniela Cilloni
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Haematologica 92:1224-9. 2007
    ..This review highlights the in vitro and in vivo results of NF-kB inhibition in myeloid malignancies...
  27. doi request reprint Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues
    Antonella Roetto
    Department of Clinical and Biological Science, University of Torino, Turin, Italy
    Blood 115:3382-9. 2010
    ..Our results strengthen the function of hepatic alpha-Tfr2 in hepcidin activation, suggest a role for extrahepatic Tfr2 and indicate that beta-Tfr2 may specifically control spleen iron efflux...
  28. doi request reprint New HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib, and nilotinib in human plasma
    Silvia De Francia
    Department of Biological and Clinical Sciences, University of Torino, S Luigi Gonzaga Hospital, 10043 Orbassano TO, Italy
    J Chromatogr B Analyt Technol Biomed Life Sci 877:1721-6. 2009
    ....
  29. ncbi request reprint Emerging targets for hematological malignancies
    Daniela Cilloni
    University of Turin, San Luigi Hospital, Department of Clinical and Biological Sciences, Gonzole 10, 10043 Orbassano Torino, Italy
    Curr Opin Drug Discov Devel 13:548-58. 2010
    ....
  30. ncbi request reprint Myelodysplastic syndromes
    Daniela Cilloni
    Dept of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano Torino, Italy
    Ann N Y Acad Sci 1028:400-8. 2004
    ..Finally, the identification of myelodysplasia-associated antigens that may be targeted by an immunotherapeutic approach represents a future perspective in tailored therapy for MDS patients...
  31. ncbi request reprint Early prediction of treatment outcome in acute myeloid leukemia by measurement of WT1 transcript levels in peripheral blood samples collected after chemotherapy
    Daniela Cilloni
    Dept of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano, Turin, Italy
    Haematologica 93:921-4. 2008
    ..WT1 helps identify patients at high risk of relapse soon after induction chemotherapy allowing post-induction therapy in high risk patients to be intensified...
  32. ncbi request reprint Genetic abnormalities as targets for molecular therapies in myelodysplastic syndromes
    Daniela Cilloni
    Department of Clinical and Biological Sciences of the University of Turin, San Luigi Hospital, Gonzole 10, 10043 Orbassano Torino, Italy
    Ann N Y Acad Sci 1089:411-23. 2006
    ..Future therapies will attempt to resolve cytopenias in MDS, eliminate malignant clones, and allow differentiation by attacking specific mechanisms of the disease...
  33. ncbi request reprint Sensitivity to imatinib therapy may be predicted by testing Wilms tumor gene expression and colony growth after a short in vitro incubation
    Daniela Cilloni
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Italy
    Cancer 101:979-88. 2004
    ....
  34. ncbi request reprint Emerging drugs for chronic myeloid leukemia
    Daniela Cilloni
    University of Turin, Department of Clinical and Biological Sciences, S Luigi Hospital, Regione Gonzole 10, 10043, Orbassano Turin, Italy
    Expert Opin Emerg Drugs 15:175-84. 2010
    ..The impressive results of TKIs in this model have been overshadowed by the development of clinical resistance...
  35. ncbi request reprint Alternative BCR/ABL splice variants in Philadelphia chromosome-positive leukemias result in novel tumor-specific fusion proteins that may represent potential targets for immunotherapy approaches
    Gisella Volpe
    Department of Clinical, University of Turin, Turin, Italy
    Cancer Res 67:5300-7. 2007
    ..We detected the presence of OOF-specific CD8+ T cells in four of four patients studied, and in one case, these T cells exhibited specific cytotoxic activity against both peptide-pulsed targets and autologous primary CML cells...
  36. ncbi request reprint Evaluation of iron status in patients with chronic hepatitis C
    M Sartori
    Department of Biological and Clinical Sciences, University of Turin, Italy
    Ital J Gastroenterol Hepatol 30:396-401. 1998
    ..To evaluate the prevalence of iron overload in chronic hepatitis C and its relationship with liver histology...
  37. ncbi request reprint WT1 overexpression: a clinically useful marker in acute and chronic myeloid leukemias
    Giuseppe Saglio
    Division of Internal Medicine and Haematology, Department of Clinical and Biological Sciences of the University of Turin, San Luigi Gonzaga Hopsital 10043, Orbassano Turin, Italy
    Hematology 10:76-8. 2005
  38. ncbi request reprint WT1 as a universal marker for minimal residual disease detection and quantification in myeloid leukemias and in myelodysplastic syndrome
    Daniela Cilloni
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Acta Haematol 112:79-84. 2004
    ....
  39. ncbi request reprint Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia: a European LeukemiaNet study
    Daniela Cilloni
    Department of Clinical and Biological Sciences, University of Turin, Turin
    J Clin Oncol 27:5195-201. 2009
    ....
  40. ncbi request reprint Point mutations of the BCL-6 gene: clinical and prognostic correlation in B-diffuse large cell lymphoma
    U Vitolo
    UOA Ematologia, Dipartimento di Oncologia, Azienda Ospedaliera S Giovanni Battista, Torino, Italy
    Leukemia 16:268-75. 2002
    ..Larger series of patients need to be analyzed to evaluate the clinical relevance of BCL-6 mutations properly...
  41. ncbi request reprint Increase in platelet count in older, poor-risk patients with acute myeloid leukemia or myelodysplastic syndrome treated with valproic acid and all-trans retinoic acid
    Chiara Pilatrino
    Department of Clinical and Biological Science, University of Turin, Turin, Italy
    Cancer 104:101-9. 2005
    ....
  42. ncbi request reprint Usefulness of quantitative assessment of Wilms tumor suppressor gene expression in chronic myeloid leukemia patients undergoing imatinib therapy
    Daniela Cilloni
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences of the University of Turin, Turin, Italy
    Semin Hematol 40:37-41. 2003
    ..In fact, the use of real-time polymerase chaine reaction (PCR) to quantitatively measure the WT1 transcript amount may be a predictor of patient response to imatinib therapy...
  43. pmc A 76-kb duplicon maps close to the BCR gene on chromosome 22 and the ABL gene on chromosome 9: possible involvement in the genesis of the Philadelphia chromosome translocation
    Giuseppe Saglio
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, University of Turin, 10043 Turin, Italy
    Proc Natl Acad Sci U S A 99:9882-7. 2002
    ....
  44. ncbi request reprint Quantitative assessment of WT1 expression by real time quantitative PCR may be a useful tool for monitoring minimal residual disease in acute leukemia patients
    D Cilloni
    Division of Hematology and Internal Medicine, Dept of Clinical and Biological Sciences of the University of Turin, Italy
    Leukemia 16:2115-21. 2002
    ....
  45. pmc Screening for mutations in the phenylalanine hydroxylase gene from Italian patients with phenylketonuria by using the chemical cleavage method: a new splice mutation
    I Dianzani
    Istituto di Clinica Pediatrica, Centro di Immunogenetica e Istocompatibilita CNR, Turin, Italy
    Am J Hum Genet 48:631-5. 1991
    ..Our results indicate that CCM analysis of amplified genomic DNA fragments can be successfully used to search for mutations in large genes whose transcripts are not readily available...
  46. ncbi request reprint Immunoglobulin and Myc gene structure in lymphnode biopsies from HIV-positive patients with LAS and lymphoma
    G Saglio
    Sezione de Clinica Medica, Departimento di Scienze Biomediche e Oncologia Umana, Torino, Italy
    Cancer Detect Prev 14:359-62. 1990
    ....
  47. ncbi request reprint Assessment of minimal residual disease (MRD) in CBFbeta/MYH11-positive acute myeloid leukemias by qualitative and quantitative RT-PCR amplification of fusion transcripts
    A Guerrasio
    Dipartimento di Scienze Cliniche e Biologiche, Universita di Torino, Orbassano, Torino, Italy
    Leukemia 16:1176-81. 2002
    ..The findings of our study, if confirmed, might confer an important predictive value to quantitative real-time PCR determinations of MRD in patients with inv(16) leukemia...
  48. doi request reprint HHV8-positive, HIV-negative multicentric Castleman's disease: early and sustained complete remission with rituximab therapy without reactivation of Kaposi sarcoma
    Paolo Nicoli
    Division of Hematology and Internal Medicine, Department of Clinical and Biological Sciences, San Luigi Gonzaga Hospital, University of Turin, Regione Gonzole 10, 10043, Orbassano, Turin, Italy
    Int J Hematol 90:392-6. 2009
    ..Our report, along with additional data present in the literature, suggests that rituximab may be an appropriate and safe first-line therapy for HIV-negative, HHV8-positive MCD...
  49. ncbi request reprint Frequency and distribution of trisomy 11 in multiple myeloma patients: relation with overexpression of CCND1 and t(11;14)
    Tommasina Guglielmelli
    Department of Clinical and Biological Sciences, University of Turin and St Luigi Hospital, Regione Gonzole 10, 10043 Orbassano, Turin, Italy
    Cancer Genet Cytogenet 173:51-6. 2007
    ..In the TC2 group, trisomy 11 may probably be considered as a recurrent polisomy of the hyperdiploid status...
  50. ncbi request reprint Detection of minimal residual disease in peripheral blood stem cells from two acute myeloid leukemia patients with trisomy 8 predicts early relapse after autologous bone marrow transplantation
    Patrizia Scaravaglio
    Dipartimento di Scienze Cliniche e Biologiche, Azienda Ospedaliera San Luigi Gonzaga, Orbassano, Torino, Italy
    Cancer Genet Cytogenet 133:98-101. 2002
    ..Although more data are needed, these results suggest that the persistence of MRD, as detected by FISH, in stem cell collections, is associated with a poor outcome in AML patients with trisomy 8 undergoing ABMT...
  51. doi request reprint Detection of humoral immune responses against WT1 antigen in patients affected by different hematological malignancies
    Paolo Nicoli
    Department of Clinical and Biological Sciences, University of Turin, Turin, Italy
    Acta Haematol 120:47-50. 2008
  52. ncbi request reprint Hematopoietic growth factors in autologous transplantation
    G C Avanzi
    Medical Clinic, Dept of Medical Science, University of Turin, Novara, Italy
    Biotherapy 10:299-308. 1998
    ..Several combinations of HGFs have been described to sustain the ex vivo survival and proliferation of these cells disclosing new opportunities in the field of stem cells transplants...
  53. ncbi request reprint From genes to therapy: the case of Philadelphia chromosome-positive leukemias
    Daniela Cilloni
    Department of Clinical and Biological Sciences, University of Turin, Hospital S Luigi Gonzaga, 10043, Orbassano Torino, Italy
    Ann N Y Acad Sci 963:306-12. 2002
    ....
  54. ncbi request reprint Very low doses of thalidomide as single agent in relapsed/refractory multiple myeloma
    Tommasina Guglielmelli
    Department of Clinical and Biological Sciences, University of Turin, Orbassano, Italy
    Acta Haematol 116:70-1. 2006
  55. ncbi request reprint Insertions generating the 5'RUNX1/3'CBFA2T1 gene in acute myeloid leukemia cases show variable breakpoints
    Giorgina Specchia
    Hematology, University of Foggia, Foggia, Italy
    Genes Chromosomes Cancer 41:86-91. 2004
    ..Our analysis revealed that insertions generating the 5'RUNX1/3'CBFA2T1 gene showed variable breakpoints; the size of the inserted elements ranged from 2.4 to 44 Mb...
  56. pmc PML targeting eradicates quiescent leukaemia-initiating cells
    Keisuke Ito
    Cancer Genetics Program, Beth Israel Deaconess Cancer Center, Department of Medicine, Harvard Medical School, New Research Building, 330 Brookline Avenue, Boston, Massachusetts 02215, USA
    Nature 453:1072-8. 2008
    ....
  57. ncbi request reprint Imatinib mesylate in the treatment of c-kit-positive acute myeloid leukemia: is this the real target?
    Michele Malagola
    Blood 105:904; author reply 905. 2005
  58. ncbi request reprint Denaturing-HPLC-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Chem 50:1205-13. 2004
    ..Point mutations within the ABL kinase domain are emerging as the most frequent mechanism for reactivation of kinase activity within the leukemic clone...
  59. ncbi request reprint Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype
    Brunangelo Falini
    Institute of Hematology, University of Perugia, Perugia, Italy
    N Engl J Med 352:254-66. 2005
    ..Nucleophosmin (NPM), a nucleocytoplasmic shuttling protein with prominent nucleolar localization, regulates the ARF-p53 tumor-suppressor pathway. Translocations involving the NPM gene cause cytoplasmic dislocation of the NPM protein...
  60. ncbi request reprint Expression of spliced oncogenic Ikaros isoforms in Philadelphia-positive acute lymphoblastic leukemia patients treated with tyrosine kinase inhibitors: implications for a new mechanism of resistance
    Ilaria Iacobucci
    Department of Hematology Oncology, L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    Blood 112:3847-55. 2008
    ..These results establish a previously unknown link between specific molecular defects that involve alternative splicing of the IKZF1 gene and the resistance to TKIs in Ph+ ALL patients...
  61. ncbi request reprint Occurrence of the same chromosome abnormalities in Ph+ and Ph- cells in chronic myeloid leukaemia. Evidence of a secondary origin of the Ph chromosome?
    Emilio Donti
    Br J Haematol 135:265-6. 2006
  62. ncbi request reprint Molecular response to imatinib in late chronic-phase chronic myeloid leukemia
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology L and A Serànoli, University of Bologna, Italy
    Blood 103:2284-90. 2004
    ..We conclude that in CCgRs the degree of MR may vary from 2 to more than 4 logs, and that there is a progressive decrease of transcript level by time. Only 1 of 22 negative cases has had a relapse as yet...
  63. ncbi request reprint Philadelphia-positive acute lymphoblastic leukemia with multiple subclones including duplication of the Philadelphia chromosome and Abelson oncogene
    Roberta La Starza
    Hematology and Bone Marrow Transplantation Unit, University of Perugia, Policlinico Monteluce, 06100, Perugia, Italy
    Cancer Genet Cytogenet 132:46-50. 2002
    ..Other molecular events involving chromosome 9 were a monoallelic loss of JAK2 in both subclones and an additional loss of P15/P16 in the subclone with the acrocentric marker bearing the extra Ph chromosome...
  64. ncbi request reprint Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia
    Hagop Kantarjian
    M D Anderson Cancer Center, Houston, TX 77030, USA
    N Engl J Med 346:645-52. 2002
    ..Chronic myelogenous leukemia (CML) is caused by the BCR-ABL tyrosine kinase, the product of the Philadelphia chromosome. Imatinib mesylate, formerly STI571, is a selective inhibitor of this kinase...
  65. ncbi request reprint Neutrophilic-chronic myeloid leukemia: low levels of p230 BCR/ABL mRNA and undetectable BCR/ABL protein may predict an indolent course
    Srdan Verstovsek
    Department of Leukemia, The University of Texas M D Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 94:2416-25. 2002
    ..The translocation (9;22) in CML-N results in the transcription of an e19/a2 type BCR/ABL mRNA that codes for a 230-kD BCR/ABL protein (p230). The indolence of the clinical course of patients with CML-N has been disputed...
  66. ncbi request reprint Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
    Brian J Druker
    Oregon Health and Science University Cancer Institute, L592, 3181 SW Sam Jackson Park Rd, Portland, OR 97239, USA
    N Engl J Med 355:2408-17. 2006
    ..Imatinib inhibits this kinase, and in a short-term study was superior to interferon alfa plus cytarabine for newly diagnosed CML in the chronic phase. For 5 years, we followed patients with CML who received imatinib as initial therapy...
  67. ncbi request reprint Novel types of bcr-abl transcript with breakpoints in BCR exon 8 found in Philadelphia positive patients with typical chronic myeloid leukemia retain the sequence encoding for the DBL- and CDC24 homology domains but not the pleckstrin homology one
    Giovanni Martinelli
    Molecular Biology Unit, Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 87:688-94; discussion 694. 2002
    ..We previously described a novel type of the chimeric bcr-abl mRNA transcript in a patient with a Philadelphia chromosome positive chronic myeloid leukemia. A similar bcr-abl transcript has also been described by others...
  68. ncbi request reprint Bcl-6 p53 mutations in lymphomas carrying the bcl-2/Jh rearrangement
    Mar Bellido
    Department of Hematology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain
    Haematologica 87:908-17. 2002
    ..Tumor cells may acquire additional molecular alterations that may be associated with histologic progression or with chemo-resistance...
  69. ncbi request reprint Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia
    Stephen G O'Brien
    University of Newcastle, Newcastle, United Kingdom
    N Engl J Med 348:994-1004. 2003
    ..We compared the efficacy of imatinib with that of interferon alfa combined with low-dose cytarabine in newly diagnosed chronic-phase CML...
  70. ncbi request reprint Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection
    Daniela Cilloni
    Blood 102:773-4; author reply 774. 2003
  71. ncbi request reprint ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chr
    Simona Soverini
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Via Massarenti 9 40138 Bologna, Italy
    J Clin Oncol 23:4100-9. 2005
    ....
  72. ncbi request reprint Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-alpha: 5-year outcome
    Francesca Palandri
    Department of Hematology and Oncology L and A Seràgnoli, St Orsola Malpighi University Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Haematologica 93:770-4. 2008
    ..Any possible additional benefit of the combination with interferon-alpha remains uncertain, due to low patient compliance...
  73. ncbi request reprint Low-dose imatinib mesylate leads to rapid induction of major molecular responses and achievement of complete molecular remission in FIP1L1-PDGFRA-positive chronic eosinophilic leukemia
    Jelena V Jovanovic
    Department of Medical and Molecular Genetics, Guy s Hospital, King s College London, UK
    Blood 109:4635-40. 2007
    ....
  74. ncbi request reprint The effects of saquinavir on imatinib-resistant chronic myelogenous leukemia cell lines
    Fabio Timeus
    Haematologica 91:711-2. 2006
    ..Association with imatinib caused a significant increase of activity...
  75. ncbi request reprint Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party
    Gianantonio Rosti
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Haematologica 92:101-5. 2007
    ..As might be expected, older patients experienced more adverse events, both hematologic and non-hematologic: this worsened compliance did not, however, prevent a long-term outcome similar to that of younger patients...
  76. ncbi request reprint Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia
    Simona Soverini
    Department of Hematology Oncology L and A Seràgnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:7374-9. 2006
    ..ABL kinase domain mutations have been implicated in the resistance to the BCR-ABL inhibitor imatinib mesylate of Philadelphia-positive (Ph+) leukemia patients...
  77. ncbi request reprint Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis
    Jorge Cortes
    M D Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Blood 109:3207-13. 2007
    ..These trials were registered at www.clinicaltrials.gov as #CA180006 and #CA180015...
  78. ncbi request reprint Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chromosome-positive leukemia
    Simona Soverini
    J Clin Oncol 24:e51-2. 2006
  79. ncbi request reprint Monitoring minimal residual disease and controlling drug resistance in chronic myeloid leukaemia patients in treatment with imatinib as a guide to clinical management
    Giovanni Martinelli
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Hematol Oncol 24:196-204. 2006
    ..We review current trends in the management of chronic myeloid leukaemia patients undergoing treatment with tyrosine kinase inhibitors...
  80. ncbi request reprint Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    Clin Cancer Res 12:3037-42. 2006
    ..CCgR is durable in the majority of patients but relapse occurs in a subset...
  81. ncbi request reprint Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi Hospital, Via Massarenti 9, 40138 Bologna, Italy
    Blood 108:1809-20. 2006
    ..The importance of regular monitoring at experienced centers was highlighted...
  82. ncbi request reprint Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain
    Simona Soverini
    Institute of Hematology and Medical Oncology L e A Seràgnoli, University of Bologna, Bologna, Italy
    Haematologica 92:401-4. 2007
    ..In all patients but one, resistance to dasatinib was invariably found to be associated with mutations at residue 315 and/or at residue 317...
  83. ncbi request reprint JAK2 V617F mutation in leukaemic transformation of philadelphia-negative chronic myeloproliferative disorders
    Davide Rossi
    Br J Haematol 135:267-8. 2006
  84. pmc Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results
    Timothy Hughes
    Institute of Medical and Veterinary Science, Adelaide, Australia
    Blood 108:28-37. 2006
    ..We recognize that our recommendations are provisional and will require revision as new evidence emerges...
  85. ncbi request reprint NPM1 mutations and cytoplasmic nucleophosmin are mutually exclusive of recurrent genetic abnormalities: a comparative analysis of 2562 patients with acute myeloid leukemia
    Brunangelo Falini
    Institute of Hematology, University of Perugia, Perugia, Italy
    Haematologica 93:439-42. 2008
    ..Taken together, these findings make NPMc+ acute myeloid leukemia a good candidate for inclusion in the upcoming World Health Organization classification...
  86. doi request reprint Monitoring treatment of chronic myeloid leukemia
    Michele Baccarani
    Haematologica 93:161-9. 2008
  87. ncbi request reprint Independent clones at separable stages of differentiation, bearing different GATA1 mutations, in the same TMD patient with Down syndrome
    Jürgen Groet
    Blood 106:1887-8. 2005
  88. doi request reprint Long-term outcome of complete cytogenetic responders after imatinib 400 mg in late chronic phase, philadelphia-positive chronic myeloid leukemia: the GIMEMA Working Party on CML
    Francesca Palandri
    Department of Hematology Oncology L and A Seràgnoli S Orsola Malpighi Hospital, University of Bologna, Bologna, Italy
    J Clin Oncol 26:106-11. 2008
    ..Imatinib mesylate (IM) has rapidly become the front-line treatment of Philadelphia-positive (Ph-pos) chronic myeloid leukemia, but the number of patients who were treated and are being treated with IM second-line is still substantial...
  89. ncbi request reprint Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study
    Pier Paolo Piccaluga
    Institute of Hematology and Medical Oncology L and A Seragnoli, S Orsola Malpighi Hospital, University of Bologna, Via Massarenti, 9, 40138 Bologna, Italy
    Haematologica 92:1721-2. 2007
    ..No patient achieved complete remission. One patient obtained a hematologic improvement (platelet increase with transfusion independence). Median overall survival was 3 months (0.5-44+). Non-hematologic toxicity was overall mild...
  90. ncbi request reprint Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia
    Philipp Le Coutre
    Campus Virchow Klinikum, Charite Universitatsmedizin, Berlin, Germany
    Blood 111:1834-9. 2008
    ..In conclusion, nilotinib is an effective and well-tolerated treatment in imatinib-resistant and -intolerant CML-AP. This trial is registered at www.clinicaltrials.gov as NCT00384228...
  91. ncbi request reprint The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRalpha-positive hypereosinophilic syndrome. Results of a multicenter prospective study
    Michele Baccarani
    Department of Hematology Oncology L and A Seràgnoli, S Orsola Malpighi University Hospital, Bologna, Italy
    Haematologica 92:1173-9. 2007
    ..These cases with FIP1L1-PDGFRalpha rearrangement have been reported to be very sensitive to the tyrosine kinase inhibitor imatinib mesylate...
  92. ncbi request reprint BCR-ABL nuclear entrapment kills human CML cells: ex vivo study on 35 patients with the combination of imatinib mesylate and leptomycin B
    Alessandra Aloisi
    Department of Biomedical Sciences, Section of General Pathology, University of Catania, Via Androne, 83 95124 Catania, Italy
    Blood 107:1591-8. 2006
    ....
  93. ncbi request reprint Comparison between patients with Philadelphia-positive chronic phase chronic myeloid leukemia who obtained a complete cytogenetic response within 1 year of imatinib therapy and those who achieved such a response after 12 months of treatment
    Ilaria Iacobucci
    Institute of Hematology and Medical Oncology Seragnoli, University of Bologna, Bologna, Italy
    J Clin Oncol 24:454-9. 2006
    ..Imatinib mesylate is a potent inhibitor of BCR-ABL, the constitutively active tyrosine kinase protein critical for the pathogenesis of chronic myeloid leukemia...
  94. ncbi request reprint The role of BCR/ABL isoforms in the presentation and outcome of patients with Philadelphia-positive acute lymphoblastic leukemia: a seven-year update of the GIMEMA 0496 trial
    Giuseppe Cimino
    Division of Hematology, Dept of Cellular Biotechnology and Hematology, University La Sapienza, Via Benevento 6, 00161 Rome, Italy
    Haematologica 91:377-80. 2006
    ..By contrast, the p190 emerged as the only independent prognostic factor favorably affecting the 5-year overall survival and disease-free survival rates (p=0.008 and p=0.02, respectively)...